Zobrazeno 1 - 10
of 184
pro vyhledávání: '"L J, Old"'
Autor:
Ronald D. Finn, P. M. Deckert, Richards Elizabeth C, Nicholas J. Montalto, M. A. Clark, C. Williams, Sydney Welt, Achim A. Jungbluth, Katherine S. Panageas, L. J. Old
Publikováno v:
International Journal of Cancer. 87:382-390
Therapeutic proteins have been conjugated with polyethylene glycol (PEGylation) to reduce immunogenicity and enhance circulating dose. Here we have investigated the effect of PEGylation on immunogenicity, pharmacokinetics, and histologic microdistrib
Autor:
Elizabeth Stockert, Kristin Iversen, D McGregor, Keren Coplan, L. J. Old, Klaus J. Busam, Achim A. Jungbluth, Yao-Tseng Chen
Publikováno v:
The American Journal of Surgical Pathology. 22:57-63
The Melan-A (MART-1) gene encodes an antigen recognized by cytotoxic T cells. It has been said to be restricted in its expression to melanocytes. However, here we report the presence of immunoreactivity for A103, an antibody to Melan-A, in five adren
Publikováno v:
Cytogenetic and Genome Research. 79:237-240
CTAG was initially cloned from an esophageal squamous cell carcinoma cDNA expression library by immunoscreening with autologous patient’s serum. CTAG mRNA is expressed in a proportion of human cancers in a lineage-nonspecific fashion, whereas its e
Autor:
J S Germain, L. J. Old, Nancy E. Kemeny, Ronald D. Finn, Chaitanya R. Divgi, Andrew M. Scott, Farhad Daghighian, Steven M. Larson, Richards Elizabeth C, Sydney Welt
Publikováno v:
Journal of Clinical Oncology. 14:1787-1797
PURPOSE A phase I/II study was designed to determine the maximum-tolerated dose (MTD) of iodine 125-labeled monoclonal antibody A33 (125I-mAb A33), its limiting organ toxicity, and the uptake and retention of radioactivity in tumor lesions. PATIENTS
Autor:
Steven M. Larson, Michael M. Graham, P. Garin-Chesa, Ronald D. Finn, Sydney Welt, Elizabeth A. Carswell, Alfred M. Cohen, Chaitanya R. Divgi, Andrew M. Scott, L. J. Old
Publikováno v:
Journal of Clinical Oncology. 12:1193-1203
PURPOSE To define the toxicity, imaging, and biodistribution characteristics of iodine 131-labeled monoclonal antibody F19 (131I-mAbF19). MAbF19 recognizes the fibroblast activation protein (FAP), a cell-surface glycoprotein not present in most norma
Publikováno v:
Journal of Clinical Oncology. 9:1749-1756
We used monoclonal antibodies to identify occult micrometastases in the bone marrow of 49 patients with operable (stage I and II) breast carcinoma. Follow-up (mean, 29 months; median, 30 months) revealed that 12 patients recurred. The presence of bon
Autor:
M. B. Moloney, H. Kalnins, Ian D. Davis, A. Sjolander, Yao-Tseng Chen, L. J. Old, Jonathan Cebon, Geoff Dumsday, W. Woods, Gerd Ritter, J. Rood, Andrew M. Scott, Glenn A Cartwright, Simon Green, Eric W. Hoffman, Roger Murphy, Darryl W. Maher, K. Healey, A. Kypridis, David Ryan, Leonard Cohen, Michael R. Rubira, Michael K. McNamara, Eugene Maraskovsky, J. Ackland
Publikováno v:
Preparative biochemistrybiotechnology. 35(2)
The cancer‐testis antigen, NY‐ESO‐1, has been engineered into a bacterial expression plasmid which incorporates a His6‐tag. The plasmid was transfected into E. coli strain BL21 and Master and Working cell banks generated from this expression
Autor:
L J, Old
Publikováno v:
Cancer immunity. 1